Pricing Log in Create free account
Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.77 2.15 +5.87%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Roivant Sciences Ltd. (ROIV) Total debt

Alert me on Total debt

Roivant Sciences Ltd.'s total debt at the end of fiscal 2024 was $442.6M, up 6.33% from $416.2M in fiscal 2023. At the end of the quarter to 30 June 2024 it was $323.7M. Roivant Sciences Ltd. ranks 40th of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2024 $442.6M 6.33%
FY2023 $416.2M 98.18%
FY2022 $210.0M 23.34%
FY2021 $170.3M —

Quarterly newest first

Period Total debt Change
Jun 2024 $323.7M (26.86%)
Mar 2024 $442.6M (1.44%)
Dec 2023 $449.0M 2.42%
Sep 2023 $438.4M 2.09%
11 more quarters

Total debt against peers

Company Total debt
RPRX Royalty Pharma PLC compare $8.6B
GMAB Genmab A/S Sponsored ADR compare $5.1B
RVMD Revolution Medicines, Inc. compare $1.0B
ALNY Alnylam Pharmaceuticals, Inc. compare $1.0B
ONC BeOne Medicines Ltd. - Sponsored ADR compare $825.2M
INSM Insmed, Inc. compare $562.8M
BNTX BioNTech SE Sponsored ADR compare $414.1M
ROIV Roivant Sciences Ltd. $323.7M
INCY Incyte Corporation compare $27.6M

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on ROIV